Legal Representation
Attorney
Scot A. Duvall
USPTO Deadlines
Next Deadline
990 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20220927)
Due Date
September 27, 2028
Grace Period Ends
March 27, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
32 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 22, 2023 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Feb 7, 2023 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Jan 18, 2023 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Jan 18, 2023 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Dec 27, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Sep 27, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 27, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 18, 2022 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Jul 12, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 12, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 29, 2022 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jun 29, 2022 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Jun 22, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 6, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 6, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jun 6, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 6, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 6, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jun 3, 2022 | DMCC | I | DATA MODIFICATION COMPLETED | Loading... |
| Jun 3, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 25, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 24, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 24, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 6, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jan 18, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jan 18, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Dec 28, 2021 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Dec 27, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 22, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 27, 2021 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jul 23, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 22, 2021 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Vaccines; diagnostic preparations for medical purposes; chemical reagents for medical or veterinary purposes; pharmaceutical preparations for the prevention and treatment of HIV/AIDS; pharmaceutical preparations for the prevention and treatment of liver diseases; pharmaceutical preparations for the prevention and treatment of respiratory system disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases, diabetes; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; drugs for medical purposes for the prevention and treatment of HIV/AIDS; drugs for medical purposes for the prevention and treatment of liver diseases; drugs for medical purposes for the prevention and treatment of respiratory system disorders; drugs for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; drugs for medical purposes for the prevention and treatment of gastro-intestinal diseases; drugs for medical purposes for the prevention and treatment of immune system related diseases and disorders; drugs for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; biological preparations for medical purposes for the prevention and treatment of HIV/AIDS; biological preparations for medical purposes for the prevention and treatment of liver diseases; biological preparations for medical purposes for the prevention and treatment of respiratory system disorders; biological preparations for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; biological preparations for medical purposes for the prevention and treatment of gastro-intestinal diseases; biological preparations for medical purposes for the prevention and treatment of immune system related diseases and disorders; biological preparations for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; medicines for human purposes for the prevention and treatment of HIV/ AIDS; medicines for human purposes for the prevention and treatment of liver diseases; medicines for human purposes for the prevention and treatment of respiratory system disorders; medicines for human purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; medicines for human purposes for the prevention and treatment of gastro-intestinal diseases; medicines for human purposes for the prevention and treatment of immune system related diseases and disorders; medicines for human purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; chemico-pharmaceutical preparations for the treatment of viral and infectious diseases, immune system related diseases, cancer, tumors and inflammation; chemical preparations for pharmaceutical purposes for the treatment of viral and infectious diseases, immune system related diseases, cancer, tumors and inflammation
First Use Anywhere:
0
First Use in Commerce:
0
Class 035
Retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Biological research; research and development of new products for others; scientific laboratory services; scientific research; chemical analysis; conducting clinical trials for others; technological research in the fields of medicine, the prevention, treatment and management of illness, health care delivery; technological research in the fields of genetics, genetic engineering, molecular biology and cellular immunology; conducting technical scientific feasibility project studies; chemistry services, namely, consultation, research and advice; chemical research
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
035
042